AKRITI PAHARI: Open Payments
NPI 1053193078 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$838 in 35 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $647 · 2025 $838
Food & beverage: $827Education: $12
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $332 |
| Novo Nordisk Inc | 6 | $128 |
| Exact Sciences Corporation | 4 | $107 |
| Amgen Inc. | 4 | $71 |
| Astellas Pharma US Inc | 3 | $70 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| Merck Sharp & Dohme LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: FANAPT, HETLIOZ, Cologuard Collection Kit, OTEZLA, Veozah, Wegovy, The Cologuard Plus Collection Kit, FARXIGA.
Industry payments across MD — which companies pay providers there.
